Article

Amgen's First-in-Class Viral Drug, T-Vec, Could Soon Be Approved by EMA

Author(s):

The drug is awaiting an FDA verdict next week.

The European Medicine Agency (EMA) has approved Amgen's tumor-killing virus, talimogene laherparepvec (T-Vec) for treating unresectable melanoma that has not metastasized. Imlygic uses a modified herpes simplex virus that is targeted to infect cancer cells alone. The virus, injected directly into the tumors, replicates and causes the cancer cells to rupture. The resulting immune system response is responsible for the antigenic response against the tumor.

The product is due for an FDA verdict by October 27, 2015.

Read more here: http://reut.rs/1W9QCJA.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
EHA 2025 Congress Recap | Image Credit: Venngage
Coral Omene, MD, PhD, sitting for a vieo interview
Ashley Yocum, PhD
Dr Matthew Matasar
Dr Xavier Leleu
Dr Marina Kremskayana
Dr Sundar Jagannath
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo